Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.
Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedType 2 diabetes and the related topics MedlinePlus Genetics were removed from the page's topics/MeSH section.SummaryDifference0.2%
- Check18 days agoChange DetectedFooter updates include adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2; core study content and details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedThe page footer shows Revision: v3.3.2, replacing v3.2.0; this is a metadata change and does not affect study details or navigation.SummaryDifference0.1%
- Check54 days agoChange DetectedRemoved the government funding status notice from the page; this change does not affect the study content (eligibility criteria, endpoints, or results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check69 days agoChange DetectedNo significant changes detected on the page; the study details page remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check76 days agoChange DetectedAdded related topics: Type 2 diabetes and MedlinePlus Genetics on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.